- Home
- / Neuren Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Neuren Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$14.1
2024-10-04
Market Capitalization
$1.9 B
2024-10-04
Revenue
$64.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| NZD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.5M | 14.6M | 231.9M | 213.2M | 64.6M | |||
| Gross profit | 14.0M | 495.0K | 817.0K | 3.2M | 15.4M | 231.9M | 213.2M | 64.6M |
| Gross profit margin, % | 105.9% | 100.0% | 100.0% | 100.0% | ||||
| Operating expense total | 12.0M | 11.8M | 9.5M | 11.4M | 16.8M | 34.9M | 37.6M | 42.6M |
| Depreciation and amortization | 78.0K | 4.0K | 6.0K | 8.0K | 10.0K | 17.0K | 22.0K | 23.0K |
| EBITDA | 2.0M | (11.3M) | (8.7M) | (8.2M) | (1.4M) | 197.0M | 175.6M | 22.1M |
| EBITDA margin, % | -9.8% | 85.0% | 82.3% | 34.1% | ||||
| EBIT | 1.9M | (11.3M) | (8.7M) | (8.2M) | (1.4M) | 197.0M | 175.6M | 22.0M |
| EBIT margin, % | -9.8% | 84.9% | 82.3% | 34.1% | ||||
| Interest income | 218.0K | 389.0K | 147.0K | 41.0K | 391.0K | 5.7M | 11.0M | |
| Pre tax profit | 3.1M | (10.8M) | (9.2M) | (7.8M) | 184.0K | 205.1M | 182.9M | 38.9M |
| Income tax expense | 48.1M | 40.9M | 8.5M | |||||
| Net Income | 3.1M | (10.8M) | (9.2M) | (7.8M) | 184.0K | 157.1M | 142.0M | 30.4M |